Taysha Gene Therapies (TSHA) Misses Q4 EPS by 58c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q4 EPS of ($0.99), $0.58 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $2.5 million versus the consensus estimate of $10 million.

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Credo Technology shares rise on analyst support and conference comments
• CMS targets 15% Medicare lab fee cuts, putting DGX and LH revenue at risk